Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Belohlavkova, S; Simak, J; Kokesova, A; Hnilickova, O; Hampl, V
   Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels
   JOURNAL OF APPLIED PHYSIOLOGY
   
   S. Belohlavkova et al., "Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels", J APP PHYSL, 91(2), 2001, pp. 755-761
2. Kaddoumi, A; Nakashima, MN; Nakashima, K
   Fluorometric determination of DL-fenfluramine, DL-norfenfluramine and phentermine in plasma by achiral and chiral high-performance liquid chromatography
   JOURNAL OF CHROMATOGRAPHY B
   
   A. Kaddoumi et al., "Fluorometric determination of DL-fenfluramine, DL-norfenfluramine and phentermine in plasma by achiral and chiral high-performance liquid chromatography", J CHROMAT B, 763(1-2), 2001, pp. 79-90
3. Kaddoumi, A; Nakashima, MN; Wada, M; Kuroda, N; Nakahara, Y; Nakashima, K
   Hplc of (+/-)-fenfluramine and phentermine in plasma after derivatization with dansyl chloride
   JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
   
   A. Kaddoumi et al., "Hplc of (+/-)-fenfluramine and phentermine in plasma after derivatization with dansyl chloride", J LIQ CHR R, 24(1), 2001, pp. 57-67
4. 
   ASHP therapeutic position statement on the safe use of pharmacotherapy forobesity management in adults
   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
   
   AM J HEAL S, 58(17), 2001, pp. 1645-1655
5. Campbell, ML; Mathys, ML
   Pharmacologic options for the treatment of obesity
   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
   
   M.L. Campbell e M.L. Mathys, "Pharmacologic options for the treatment of obesity", AM J HEAL S, 58(14), 2001, pp. 1301-1308
6. Poston, WSC; Haddock, CK; Dill, PL; Thayer, B; Foreyt, JP
   Lifestyle treatments in randomized clinical trials of pharmacotherapies for obesity
   OBESITY RESEARCH
   
   W.S.C. Poston et al., "Lifestyle treatments in randomized clinical trials of pharmacotherapies for obesity", OBES RES, 9(9), 2001, pp. 552-563
7. Callahan, BT; Cord, BJ; Ricaurte, GA
   Long-term impairment of anterograde axonal transport along fiber projection originating in the rostral raphe nuclei after treatment with fenfluramineor methylenedioxymethamphetamine
   SYNAPSE
   
   B.T. Callahan et al., "Long-term impairment of anterograde axonal transport along fiber projection originating in the rostral raphe nuclei after treatment with fenfluramineor methylenedioxymethamphetamine", SYNAPSE, 40(2), 2001, pp. 113-121
8. Prow, MR; Lancashire, B; Aspley, S; Heal, DJ; Kilpatrick, IC
   Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine
   INTERNATIONAL JOURNAL OF OBESITY
   
   M.R. Prow et al., "Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine", INT J OBES, 25(10), 2001, pp. 1450-1453
9. Kaddoumi, A; Kubota, A; Nakashima, MN; Takahashi, M; Nakashima, K
   High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label
   BIOMEDICAL CHROMATOGRAPHY
   
   A. Kaddoumi et al., "High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label", BIOMED CHRO, 15(6), 2001, pp. 379-388
10. Boschmann, M; Adams, F; Klaus, S
    In situ metabolic and hemodynamic response to dexfenfluramine in white adipose tissue of rats
    ANNALS OF NUTRITION AND METABOLISM
    
    M. Boschmann et al., "In situ metabolic and hemodynamic response to dexfenfluramine in white adipose tissue of rats", ANN NUTR M, 45(1), 2001, pp. 24-29
11. Burger, AJ; Charlamb, MJ; Singh, S; Notarianni, M; Blackburn, GL; Sherman, HB
    Low risk of significant echocardiographic valvulopathy in patients treatedwith anorectic drugs
    INTERNATIONAL JOURNAL OF CARDIOLOGY
    
    A.J. Burger et al., "Low risk of significant echocardiographic valvulopathy in patients treatedwith anorectic drugs", INT J CARD, 79(2-3), 2001, pp. 159-165
12. Russell, BR; Laverty, R
    The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-induced changes in temperature, activity, and neurotoxicity
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    
    B.R. Russell e R. Laverty, "The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-induced changes in temperature, activity, and neurotoxicity", PHARM BIO B, 68(3), 2001, pp. 565-574
13. Caccitolo, JA; Connolly, HM; Rubenson, DS; Orszulak, TA; Schaff, HV
    Operation for anorexigen-associated valvular heart disease
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
    
    J.A. Caccitolo et al., "Operation for anorexigen-associated valvular heart disease", J THOR SURG, 122(4), 2001, pp. 656-664
14. Perchenet, L; Hilfiger, L; Mizrahi, J; Clement-Chomienne, O
    Effects of anorexinogen agents on cloned voltage-gated K+ channel hKv1.5
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    
    L. Perchenet et al., "Effects of anorexinogen agents on cloned voltage-gated K+ channel hKv1.5", J PHARM EXP, 298(3), 2001, pp. 1108-1119
15. Higgins, GA; Ouagazzal, AM; Grottick, AJ
    Influence of the 5-HT2C receptor antagonist SB242,084 on behaviour produced by the 5-HT2 agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine
    BRITISH JOURNAL OF PHARMACOLOGY
    
    G.A. Higgins et al., "Influence of the 5-HT2C receptor antagonist SB242,084 on behaviour produced by the 5-HT2 agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine", BR J PHARM, 133(4), 2001, pp. 459-466
16. Doucet, E; St-Pierre, S; Almeras, N; Despres, JP; Bouchard, C; Tremblay, A
    Evidence for the existence of adaptive thermogenesis during weight loss
    BRITISH JOURNAL OF NUTRITION
    
    E. Doucet et al., "Evidence for the existence of adaptive thermogenesis during weight loss", BR J NUTR, 85(6), 2001, pp. 715-723
17. Trifunovic, R; Reilly, S
    Medial versus lateral parabrachial nucleus lesions in the rat: effects on cholecystokinin- and D-fenfluramine-induced anorexia
    BRAIN RESEARCH
    
    R. Trifunovic e S. Reilly, "Medial versus lateral parabrachial nucleus lesions in the rat: effects on cholecystokinin- and D-fenfluramine-induced anorexia", BRAIN RES, 894(2), 2001, pp. 288-296
18. Davidoff, R; McTiernan, A; Constantine, G; Davis, KD; Balady, GJ; Mendes, LA; Rudolph, RE; Bowen, DJ
    Echocardiographic examination of women previously treated with fenfluramine - Long-term follow-up of a randomized, double-blind, placebo-controlled trial
    ARCHIVES OF INTERNAL MEDICINE
    
    R. Davidoff et al., "Echocardiographic examination of women previously treated with fenfluramine - Long-term follow-up of a randomized, double-blind, placebo-controlled trial", ARCH IN MED, 161(11), 2001, pp. 1429-1436
19. Mast, ST; Jollis, JG; Ryan, T; Anstrom, KJ; Crary, JL
    The progression of fenfluramine-associated valvular heart disease assessedby echocardiography
    ANNALS OF INTERNAL MEDICINE
    
    S.T. Mast et al., "The progression of fenfluramine-associated valvular heart disease assessedby echocardiography", ANN INT MED, 134(4), 2001, pp. 261-266
20. Sutton, MS
    Silver lining to the cloud over anorexogen-related cardiac valvulopathy?
    ANNALS OF INTERNAL MEDICINE
    
    M.S. Sutton, "Silver lining to the cloud over anorexogen-related cardiac valvulopathy?", ANN INT MED, 134(4), 2001, pp. 335-337
21. Carr, ME; Carr, SL; Martin, EJ; Johnson, BA
    Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine - A case report
    ANGIOLOGY
    
    M.E. Carr et al., "Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine - A case report", ANGIOLOGY, 52(5), 2001, pp. 361-366
22. Weissman, NJ
    Appetite suppressants and valvular heart disease
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES
    
    N.J. Weissman, "Appetite suppressants and valvular heart disease", AM J MED SC, 321(4), 2001, pp. 285-291
23. Mchelakis, ED; Weir, EK
    Anorectic drugs and pulmonary hypertension from the bedside to the bench
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES
    
    E.D. Mchelakis e E.K. Weir, "Anorectic drugs and pulmonary hypertension from the bedside to the bench", AM J MED SC, 321(4), 2001, pp. 292-299
24. Mast, ST; Gersing, KR; Anstrom, KJ; Krishnan, KR; Califf, RM; Jollis, JG
    Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation
    AMERICAN JOURNAL OF CARDIOLOGY
    
    S.T. Mast et al., "Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation", AM J CARD, 87(8), 2001, pp. 989-993
25. Foltin, RW
    Effects of amphetamine, dexfenfluramine, diazepam, and other pharmacological and dietary manipulations on food "seeking" and "taking" behavior in non-human primates
    PSYCHOPHARMACOLOGY
    
    R.W. Foltin, "Effects of amphetamine, dexfenfluramine, diazepam, and other pharmacological and dietary manipulations on food "seeking" and "taking" behavior in non-human primates", PSYCHOPHAR, 158(1), 2001, pp. 28-38
26. Rowland, NE; Lo, J; Robertson, K
    Acute anorectic effect of single and combined drugs in mice using a non-deprivation protocol
    PSYCHOPHARMACOLOGY
    
    N.E. Rowland et al., "Acute anorectic effect of single and combined drugs in mice using a non-deprivation protocol", PSYCHOPHAR, 157(2), 2001, pp. 193-196
27. Scheen, AJ; Lefebvre, PJ
    Antiobesity pharmacotherapy in the management of Type 2 diabetes
    DIABETES-METABOLISM RESEARCH AND REVIEWS
    
    A.J. Scheen e P.J. Lefebvre, "Antiobesity pharmacotherapy in the management of Type 2 diabetes", DIABET M R, 16(2), 2000, pp. 114-124
28. Watts, GF; Herrmann, S; Riches, FM
    Effects of diet and serotonergic agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men
    QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS
    
    G.F. Watts et al., "Effects of diet and serotonergic agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men", QJM-MON J A, 93(3), 2000, pp. 153-161
29. Ryan, DH
    Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity
    ENDOCRINE
    
    D.H. Ryan, "Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity", ENDOCRINE, 13(2), 2000, pp. 193-199
30. Ziegler, O; Quilliot, D
    Drug therapy of obesity in type 2 diabetes mellitus.
    DIABETES & METABOLISM
    
    O. Ziegler e D. Quilliot, "Drug therapy of obesity in type 2 diabetes mellitus.", DIABETE MET, 26, 2000, pp. 34-41
31. Hirsch, J; Mackintosh, RM; Aronne, LJ
    The effects of drugs used to treat obesity on the autonomic nervous system
    OBESITY RESEARCH
    
    J. Hirsch et al., "The effects of drugs used to treat obesity on the autonomic nervous system", OBES RES, 8(3), 2000, pp. 227-233
32. Khan, MA; St Peter, JV; Breen, GA; Hartley, GG; Vessey, JT
    Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants
    OBESITY RESEARCH
    
    M.A. Khan et al., "Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants", OBES RES, 8(1), 2000, pp. 43-48
33. Rossner, S; Sjostrom, L; Noack, R; Meinders, AE; Noseda, G
    Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
    OBESITY RESEARCH
    
    S. Rossner et al., "Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity", OBES RES, 8(1), 2000, pp. 49-61
34. Deitel, M
    From the editor's desk .... Fenfluramines and heart valves
    OBESITY SURGERY
    
    M. Deitel, "From the editor's desk .... Fenfluramines and heart valves", OBES SURG, 10(5), 2000, pp. 387-388
35. Jagroop, IA; Mikhailidis, DP
    An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models
    PLATELETS
    
    I.A. Jagroop e D.P. Mikhailidis, "An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models", PLATELETS, 11(3), 2000, pp. 161-165
36. Callahan, BT; Yuan, J; Ricaurte, GA
    Fluoxetine increases the anorectic and long-term dopamine-depleting effects of phentermine
    SYNAPSE
    
    B.T. Callahan et al., "Fluoxetine increases the anorectic and long-term dopamine-depleting effects of phentermine", SYNAPSE, 38(4), 2000, pp. 471-476
37. Carvajal, A; del Pozo, JG; de Diego, IM; de Castro, AMR; Velasco, A
    Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: A meta-analysis
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    
    A. Carvajal et al., "Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: A meta-analysis", METH FIND E, 22(5), 2000, pp. 285-290
38. Piccinini, M; Rabbone, I; Novi, RF; Alberto, G; Mostert, M; Musso, A; Vai, S; Gamba, S; Rinaudo, MT
    In obese individuals dexfenfluramine corrects molecular derangements reflecting insulin resistance
    INTERNATIONAL JOURNAL OF OBESITY
    
    M. Piccinini et al., "In obese individuals dexfenfluramine corrects molecular derangements reflecting insulin resistance", INT J OBES, 24(6), 2000, pp. 735-741
39. Finer, N; James, WPT; Kopelman, PG; Lean, MEJ; Williams, G
    One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
    INTERNATIONAL JOURNAL OF OBESITY
    
    N. Finer et al., "One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor", INT J OBES, 24(3), 2000, pp. 306-313
40. Maccario, M; Grottoli, S; DiVito, L; Rossetto, R; Tassone, F; Ganzaroli, C; Oleandri, SE; Arvat, E; Ghigo, E
    Adrenal responsiveness to high, low and very low ACTH 1-24 doses in obesity
    CLINICAL ENDOCRINOLOGY
    
    M. Maccario et al., "Adrenal responsiveness to high, low and very low ACTH 1-24 doses in obesity", CLIN ENDOCR, 53(4), 2000, pp. 437-444
41. Gay, C; Shane-McWhorter, L; Williams, K; Stone, MB
    Physician prescribing of anorexigenics for weight loss in Salt Lake County, Utah
    PHARMACOTHERAPY
    
    C. Gay et al., "Physician prescribing of anorexigenics for weight loss in Salt Lake County, Utah", PHARMACOTHE, 20(8), 2000, pp. 969-975
42. Rothman, RB; Carroll, FI
    Opportunities for medication development in obesity
    DRUG DEVELOPMENT RESEARCH
    
    R.B. Rothman e F.I. Carroll, "Opportunities for medication development in obesity", DRUG DEV R, 51(2), 2000, pp. 49-51
43. Romach, MK; Sellers, EM; Kaplan, HL; Somer, GR; Gomez-Mancilla, B
    Efficacy of dexfenfluramine in the treatment of alcohol dependence
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
    
    M.K. Romach et al., "Efficacy of dexfenfluramine in the treatment of alcohol dependence", ALC CLIN EX, 24(10), 2000, pp. 1534-1541
44. Cheetham, SC; Viggers, JA; Slater, NA; Heal, DJ
    Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine
    NEUROPHARMACOLOGY
    
    S.C. Cheetham et al., "Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine", NEUROPHARM, 39(11), 2000, pp. 2028-2035
45. Hensrud, DD
    Pharmacotherapy for obesity
    MEDICAL CLINICS OF NORTH AMERICA
    
    D.D. Hensrud, "Pharmacotherapy for obesity", MED CLIN NA, 84(2), 2000, pp. 463
46. Teramae, CY; Connolly, HM; Grogan, M; Miller, FA
    Diet drug-related cardiac valve disease: The Mayo Clinic EchocardiographicLaboratory experience
    MAYO CLINIC PROCEEDINGS
    
    C.Y. Teramae et al., "Diet drug-related cardiac valve disease: The Mayo Clinic EchocardiographicLaboratory experience", MAYO CLIN P, 75(5), 2000, pp. 456-461
47. Gardier, AM; Moratalla, R; Cuellar, B; Sacerdote, M; Guibert, B; Lebrec, H; Graybiel, AM
    Interaction between the serotoninergic and dopaminergic systems in d-fenfluramine-induced activation of c-fos and jun B genes in rat striatal neurons
    JOURNAL OF NEUROCHEMISTRY
    
    A.M. Gardier et al., "Interaction between the serotoninergic and dopaminergic systems in d-fenfluramine-induced activation of c-fos and jun B genes in rat striatal neurons", J NEUROCHEM, 74(4), 2000, pp. 1363-1373
48. Patnaude, LA; Undem, BJ; O'Rourke, ST
    Dexfenfluramine-induced contraction of human and rat isolated pulmonary arteries
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    L.A. Patnaude et al., "Dexfenfluramine-induced contraction of human and rat isolated pulmonary arteries", EUR J PHARM, 401(2), 2000, pp. 229-234
49. Cheng, TO
    Fen/phen and valvular heart disease: The final link has now been established
    CIRCULATION
    
    T.O. Cheng, "Fen/phen and valvular heart disease: The final link has now been established", CIRCULATION, 102(24), 2000, pp. E180-E180
50. Rothman, RB; Baumann, MH; Savage, JE; Rauser, L; McBride, A; Hufeisen, SJ; Roth, BL
    Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications
    CIRCULATION
    
    R.B. Rothman et al., "Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications", CIRCULATION, 102(23), 2000, pp. 2836-2841
51. Rothman, RB; Redmon, JB; Raatz, SK; Kwong, CA; Swanson, JE; Bantle, JP
    Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin
    AMERICAN JOURNAL OF CARDIOLOGY
    
    R.B. Rothman et al., "Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin", AM J CARD, 85(7), 2000, pp. 913
52. Ellrott, T
    Current efforts in the drug treatment of obesity
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
    
    T. Ellrott, "Current efforts in the drug treatment of obesity", DEUT MED WO, 125(9), 2000, pp. 256-261
53. Schmued, L; Slikker, W; Clausing, P; Bowyer, J
    d-fenfluramine produces neuronal degeneration in localized regions of the cortex, thalamus, and cerebellum of the rat
    TOXICOLOGICAL SCIENCES
    
    L. Schmued et al., "d-fenfluramine produces neuronal degeneration in localized regions of the cortex, thalamus, and cerebellum of the rat", TOXICOL SCI, 48(1), 1999, pp. 100-106
54. Ryan, DH; Bray, GA; Helmcke, F; Sander, G; Volaufova, J; Greenway, F; Subramaniam, P; Glancy, DL
    Serial echocardiographic and clinical evaluation of valvular regurgitationbefore, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine
    OBESITY RESEARCH
    
    D.H. Ryan et al., "Serial echocardiographic and clinical evaluation of valvular regurgitationbefore, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine", OBES RES, 7(4), 1999, pp. 313-322
55. Steffee, CH; Singh, HK; Chitwood, WR
    Histologic changes in three explanted native cardiac valves following use of fenfluramines
    CARDIOVASCULAR PATHOLOGY
    
    C.H. Steffee et al., "Histologic changes in three explanted native cardiac valves following use of fenfluramines", CARDIO PATH, 8(5), 1999, pp. 245-253
56. Lane, DA; Kramer, MS
    Determining exposure underreporting in pharmacoepidemiologic case-control studies: Methods and example
    JOURNAL OF CLINICAL EPIDEMIOLOGY
    
    D.A. Lane e M.S. Kramer, "Determining exposure underreporting in pharmacoepidemiologic case-control studies: Methods and example", J CLIN EPID, 52(12), 1999, pp. 1279-1287
57. Yeh, SY
    Effects of antihistamines on fenfluramine-induced depletion of indoles in the brain of rats
    SYNAPSE
    
    S.Y. Yeh, "Effects of antihistamines on fenfluramine-induced depletion of indoles in the brain of rats", SYNAPSE, 32(4), 1999, pp. 301-311
58. Chassany, O; Duracinsky, M
    Ethics and clinical trials
    FUNDAMENTAL & CLINICAL PHARMACOLOGY
    
    O. Chassany e M. Duracinsky, "Ethics and clinical trials", FUN CL PHAR, 13(4), 1999, pp. 437-444
59. Oleandri, SE; Maccario, M; Rossetto, R; Procopio, M; Grottoli, S; Avogadri, E; Gauna, C; Ganzaroli, C; Ghigo, E
    Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
    
    S.E. Oleandri et al., "Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity", J ENDOC INV, 22(2), 1999, pp. 134-140
60. Yamane, F; Tohyama, Y; Diksic, M
    Acute and chronic D-fenfluramine treatments have different effects on serotonin synthesis rates in the rat brain: An autoradiographic study
    NEUROCHEMICAL RESEARCH
    
    F. Yamane et al., "Acute and chronic D-fenfluramine treatments have different effects on serotonin synthesis rates in the rat brain: An autoradiographic study", NEUROCHEM R, 24(12), 1999, pp. 1611-1620
61. Wellman, PJ; Maher, TJ
    Synergistic interactions between fenfluramine and phentermine
    INTERNATIONAL JOURNAL OF OBESITY
    
    P.J. Wellman e T.J. Maher, "Synergistic interactions between fenfluramine and phentermine", INT J OBES, 23(7), 1999, pp. 723-732
62. Walsh, KM; Leen, E; Lean, MEJ
    The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females
    INTERNATIONAL JOURNAL OF OBESITY
    
    K.M. Walsh et al., "The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females", INT J OBES, 23(10), 1999, pp. 1009-1015
63. Hauner, H
    The impact of pharmacotherapy on weight management in type 2 diabetes
    INTERNATIONAL JOURNAL OF OBESITY
    
    H. Hauner, "The impact of pharmacotherapy on weight management in type 2 diabetes", INT J OBES, 23, 1999, pp. S12-S17
64. Scheen, AJ; Lefebvre, PJ
    Pharmacological treatment of obesity: present status
    INTERNATIONAL JOURNAL OF OBESITY
    
    A.J. Scheen e P.J. Lefebvre, "Pharmacological treatment of obesity: present status", INT J OBES, 23, 1999, pp. 47-53
65. Derby, LE; Myers, MW; Jick, H
    Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    L.E. Derby et al., "Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke", BR J CL PH, 47(5), 1999, pp. 565-569
66. Redmon, JB; Raatz, SK; Kwong, CA; Swanson, JE; Thomas, W; Bantle, JP
    Pharmacologic induction of weight loss to treat type 2 diabetes
    DIABETES CARE
    
    J.B. Redmon et al., "Pharmacologic induction of weight loss to treat type 2 diabetes", DIABET CARE, 22(6), 1999, pp. 896-903
67. Kolanowski, J
    A risk-benefit assessment of anti-obesity drugs
    DRUG SAFETY
    
    J. Kolanowski, "A risk-benefit assessment of anti-obesity drugs", DRUG SAFETY, 20(2), 1999, pp. 119-131
68. Psaty, BM; Weiss, NS; Furberg, CD; Koepsell, TD; Siscovick, DS; Rosendaal, FR; Smith, NL; Heckbert, SR; Kaplan, RC; Lin, DY; Fleming, TR; Wagner, EH
    Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    
    B.M. Psaty et al., "Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease", J AM MED A, 282(8), 1999, pp. 786-790
69. Gillen, G; Porter, JR; Svec, F
    Synergistic anorectic effect of dehydroepiandrosterone and d-fenfluramine on the obese Zucker rat
    PHYSIOLOGY & BEHAVIOR
    
    G. Gillen et al., "Synergistic anorectic effect of dehydroepiandrosterone and d-fenfluramine on the obese Zucker rat", PHYSL BEHAV, 67(2), 1999, pp. 173-179
70. Rocher, C; Jacquot, C; Gardier, AM
    Simultaneous effects of local dexfenfluramine application on extracellularglutamate and serotonin levels in rat frontal cortex: a reverse microdialysis study
    NEUROPHARMACOLOGY
    
    C. Rocher et al., "Simultaneous effects of local dexfenfluramine application on extracellularglutamate and serotonin levels in rat frontal cortex: a reverse microdialysis study", NEUROPHARM, 38(4), 1999, pp. 513-523
71. Soriguer, FJC; Tinahones, FJ
    The principle of precaution and drug treatment for obesity
    MEDICINA CLINICA
    
    F.J.C. Soriguer e F.J. Tinahones, "The principle of precaution and drug treatment for obesity", MED CLIN, 112(13), 1999, pp. 503-507
72. Hensrud, DD; Connolly, HM; Grogan, M; Miller, FA; Bailey, KR; Jensen, MD
    Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine
    MAYO CLINIC PROCEEDINGS
    
    D.D. Hensrud et al., "Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine", MAYO CLIN P, 74(12), 1999, pp. 1191-1197
73. Stewart, CW; Slikker, W
    Hyperthermia-enhanced serotonin (5-HT) depletion resulting from D-fenfluramine exposure is preventable.
    LIFE SCIENCES
    
    C.W. Stewart e W. Slikker, "Hyperthermia-enhanced serotonin (5-HT) depletion resulting from D-fenfluramine exposure is preventable.", LIFE SCI, 65(15), 1999, pp. 1531-1536
74. Cogan, JC
    A new national health agenda: Providing the public with accurate information
    JOURNAL OF SOCIAL ISSUES
    
    J.C. Cogan, "A new national health agenda: Providing the public with accurate information", J SOC ISSUE, 55(2), 1999, pp. 383-400
75. Farber, HW; Loscalzo, J
    Prothrombotic mechanisms in primary pulmonary hypertension
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE
    
    H.W. Farber e J. Loscalzo, "Prothrombotic mechanisms in primary pulmonary hypertension", J LA CL MED, 134(6), 1999, pp. 561-566
76. Roth, JD; Rowland, NE
    Anorectic efficacy of the fenfluramine phentermine combination in rats: additivity or synergy?
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    J.D. Roth e N.E. Rowland, "Anorectic efficacy of the fenfluramine phentermine combination in rats: additivity or synergy?", EUR J PHARM, 373(2-3), 1999, pp. 127-134
77. Higenbottam, T; Marriott, H; Cremona, G; Laude, E; Bee, D
    The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance
    CHEST
    
    T. Higenbottam et al., "The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance", CHEST, 116(4), 1999, pp. 921-930
78. Shively, BK; Roldan, CA; Gill, EA; Najarian, T; Loar, SB
    Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine
    CIRCULATION
    
    B.K. Shively et al., "Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine", CIRCULATION, 100(21), 1999, pp. 2161-2167
79. Christensen, JD; Yurgelun-Todd, DA; Babb, SM; Gruber, SA; Cohen, BM; Renshaw, PF
    Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy
    BRAIN RESEARCH
    
    J.D. Christensen et al., "Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy", BRAIN RES, 834(1-2), 1999, pp. 1-5
80. Rowland, NE; Richmond, RM
    Area postrema and the anorectic actions of dexfenfluramine and amylin
    BRAIN RESEARCH
    
    N.E. Rowland e R.M. Richmond, "Area postrema and the anorectic actions of dexfenfluramine and amylin", BRAIN RES, 820(1-2), 1999, pp. 86-91
81. Adams, C; Cohen, A
    Appetite-suppressant drugs and heart valve abnormalities.
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX
    
    C. Adams e A. Cohen, "Appetite-suppressant drugs and heart valve abnormalities.", ARCH MAL C, 92(9), 1999, pp. 1213-1219
82. Apfelbaum, M; Vague, P; Ziegler, O; Hanotin, C; Thomas, F; Leutenegger, E
    Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
    AMERICAN JOURNAL OF MEDICINE
    
    M. Apfelbaum et al., "Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine", AM J MED, 106(2), 1999, pp. 179-184
83. Ditschuneit, HH; Flechtner-Mors, M; Johnson, TD; Adler, G
    Metabolic and weight-loss effects of a long-term dietary intervention in obese patients
    AMERICAN JOURNAL OF CLINICAL NUTRITION
    
    H.H. Ditschuneit et al., "Metabolic and weight-loss effects of a long-term dietary intervention in obese patients", AM J CLIN N, 69(2), 1999, pp. 198-204
84. Kimmel, SE; Keane, MG; Crary, JL; Jones, J; Kinman, JL; Beare, J; Sammel, M; Sutton, MS; Strom, BL
    Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota
    AMERICAN JOURNAL OF CARDIOLOGY
    
    S.E. Kimmel et al., "Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota", AM J CARD, 84(3), 1999, pp. 304-308
85. Grayburn, PA; Brickner, ME; Rutherford, JD
    The clinical dilemma of anorectic drug use and valvular heart disease
    AMERICAN JOURNAL OF CARDIOLOGY
    
    P.A. Grayburn et al., "The clinical dilemma of anorectic drug use and valvular heart disease", AM J CARD, 84(3), 1999, pp. 324
86. Munzar, P; Baumann, MH; Shoaib, M; Goldberg, SR
    Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats
    PSYCHOPHARMACOLOGY
    
    P. Munzar et al., "Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats", PSYCHOPHAR, 141(3), 1999, pp. 287-296
87. SCHEEN AJ
    AGGRESSIVE WEIGHT-REDUCTION TREATMENT IN THE MANAGEMENT OF TYPE-2 DIABETES
    DIABETES & METABOLISM
    
    A.J. Scheen, "AGGRESSIVE WEIGHT-REDUCTION TREATMENT IN THE MANAGEMENT OF TYPE-2 DIABETES", DIABETES & METABOLISM, 24(2), 1998, pp. 116-123
88. CERULLI J; MALONE M
    OUTCOMES OF PHARMACOLOGICAL AND SURGICAL-TREATMENT FOR OBESITY
    PharmacoEconomics
    
    J. Cerulli e M. Malone, "OUTCOMES OF PHARMACOLOGICAL AND SURGICAL-TREATMENT FOR OBESITY", PharmacoEconomics, 14(3), 1998, pp. 269-283
89. ORTEGA RM; ANDRES P
    IS OBESITY WORTH TREATING IN THE ELDERLY
    Drugs & aging
    
    R.M. Ortega e P. Andres, "IS OBESITY WORTH TREATING IN THE ELDERLY", Drugs & aging, 12(2), 1998, pp. 97-101
90. Tuder, RM; Radisavljevic, Z; Shroyer, KR; Polak, JM; Voelkel, NF
    Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
    
    R.M. Tuder et al., "Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension", AM J R CRIT, 158(6), 1998, pp. 1999-2001
91. ROLLS BJ; SHIDE DJ; THORWART ML; ULBRECHT JS
    SIBUTRAMINE REDUCES FOOD-INTAKE IN NON-DIETING WOMEN WITH OBESITY
    Obesity research
    
    B.J. Rolls et al., "SIBUTRAMINE REDUCES FOOD-INTAKE IN NON-DIETING WOMEN WITH OBESITY", Obesity research, 6(1), 1998, pp. 1-11
92. GONZALEZ AM; SMITH APL; EMERY CJ; HIGENBOTTAM TW
    THE PULMONARY HYPERTENSIVE FAWN-HOODED RAT HAS A NORMAL SEROTONIN TRANSPORTER CODING SEQUENCE
    American journal of respiratory cell and molecular biology
    
    A.M. Gonzalez et al., "THE PULMONARY HYPERTENSIVE FAWN-HOODED RAT HAS A NORMAL SEROTONIN TRANSPORTER CODING SEQUENCE", American journal of respiratory cell and molecular biology, 19(2), 1998, pp. 245-249
93. HARITOS VS; CHING MS; GHABRIAL H; GROSS AS; TAAVITSAINEN P; PELKONEN O; BATTAGLIA SE; SMALLWOOD RA; AHOKAS JT
    METABOLISM OF DEXFENFLURAMINE IN HUMAN LIVER-MICROSOMES AND BY RECOMBINANT ENZYMES - ROLE OF CYP2D6 AND 1A2
    Pharmacogenetics
    
    V.S. Haritos et al., "METABOLISM OF DEXFENFLURAMINE IN HUMAN LIVER-MICROSOMES AND BY RECOMBINANT ENZYMES - ROLE OF CYP2D6 AND 1A2", Pharmacogenetics, 8(5), 1998, pp. 423-432
94. BENGEL D; ISAACS KR; HEILS A; LESCH KP; MURPHY DL
    THE APPETITE-SUPPRESSANT D-FENFLURAMINE INDUCES APOPTOSIS IN HUMAN SEROTONERGIC CELLS
    NeuroReport
    
    D. Bengel et al., "THE APPETITE-SUPPRESSANT D-FENFLURAMINE INDUCES APOPTOSIS IN HUMAN SEROTONERGIC CELLS", NeuroReport, 9(13), 1998, pp. 2989-2993
95. VANGAAL LF; WAUTERS MA; DELEEUW IH
    ANTIOBESITY DRUGS - WHAT DOES SIBUTRAMINE OFFER - AN ANALYSIS OF ITS POTENTIAL CONTRIBUTION TO OBESITY TREATMENT
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    
    L.F. Vangaal et al., "ANTIOBESITY DRUGS - WHAT DOES SIBUTRAMINE OFFER - AN ANALYSIS OF ITS POTENTIAL CONTRIBUTION TO OBESITY TREATMENT", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 106, 1998, pp. 35-39
96. VEENING JG; COOLEN LM; SPOOREN WJPM; JOOSTEN H; VANOORSCHOT R; MOS J; RONKEN E; OLIVIER B
    PATTERNS OF C-FOS EXPRESSION INDUCED BY FLUVOXAMINE ARE DIFFERENT AFTER ACUTE VS. CHRONIC ORAL-ADMINISTRATION
    European neuropsychopharmacology
    
    J.G. Veening et al., "PATTERNS OF C-FOS EXPRESSION INDUCED BY FLUVOXAMINE ARE DIFFERENT AFTER ACUTE VS. CHRONIC ORAL-ADMINISTRATION", European neuropsychopharmacology, 8(3), 1998, pp. 213-226
97. DELCROIX M; KURZ X; WALCKIERS D; DEMEDTS M; NAEIJE R
    HIGH-INCIDENCE OF PRIMARY PULMONARY-HYPERTENSION ASSOCIATED WITH APPETITE-SUPPRESSANTS IN BELGIUM
    The European respiratory journal
    
    M. Delcroix et al., "HIGH-INCIDENCE OF PRIMARY PULMONARY-HYPERTENSION ASSOCIATED WITH APPETITE-SUPPRESSANTS IN BELGIUM", The European respiratory journal, 12(2), 1998, pp. 271-276
98. MCCANN UD; JIE Y; RICAURTE GA
    NEUROTOXIC EFFECTS OF (+ -)FENFLURAMINE AND PHENTERMINE, ALONE AND INCOMBINATION, ON MONOAMINE NEURONS IN THE MOUSE-BRAIN/
    Synapse
    
    U.D. Mccann et al., "NEUROTOXIC EFFECTS OF (+ -)FENFLURAMINE AND PHENTERMINE, ALONE AND INCOMBINATION, ON MONOAMINE NEURONS IN THE MOUSE-BRAIN/", Synapse, 30(3), 1998, pp. 239-246
99. BAUMANN MH; ROTHMAN RB
    COMBINED PHENTERMINE FENFLURAMINE ADMINISTRATION AND CENTRAL SEROTONIN NEURONS/
    Synapse
    
    M.H. Baumann e R.B. Rothman, "COMBINED PHENTERMINE FENFLURAMINE ADMINISTRATION AND CENTRAL SEROTONIN NEURONS/", Synapse, 28(4), 1998, pp. 339-342
100. MANNING RM; JUNG RT; LEESE GP; NEWTON RW
     THE COMPARISON OF 4 WEIGHT-REDUCTION STRATEGIES AIMED AT OVERWEIGHT PATIENTS WITH DIABETES-MELLITUS - 4-YEAR FOLLOW-UP
     Diabetic medicine
     
     R.M. Manning et al., "THE COMPARISON OF 4 WEIGHT-REDUCTION STRATEGIES AIMED AT OVERWEIGHT PATIENTS WITH DIABETES-MELLITUS - 4-YEAR FOLLOW-UP", Diabetic medicine, 15(6), 1998, pp. 497-502